4.8 Article

R-spondins engage heparan sulfate proteoglycans to potentiate WNT signaling

期刊

ELIFE
卷 9, 期 -, 页码 -

出版社

ELIFE SCIENCES PUBLICATIONS LTD
DOI: 10.7554/eLife.54469

关键词

-

类别

资金

  1. National Institutes of Health [GM118082, AI141970]
  2. American Heart Association [14POST20370057]
  3. Alex's Lemonade Stand Foundation for Childhood Cancer
  4. National Institutes of Health
  5. Cancer Research UK [C20724/A14414, C20724/A26752]
  6. European Research Council [647278]
  7. Burroughs Wellcome Fund
  8. Dutch Cancer Society Oncode Institute
  9. Nederlandse Organisatie voor Wetenschappelijk Onderzoek [91815604, 91218050]
  10. Stanford Dean's Fund
  11. NATIONAL CANCER INSTITUTE [ZIABC010891, ZIABC011901] Funding Source: NIH RePORTER
  12. European Research Council (ERC) [647278] Funding Source: European Research Council (ERC)

向作者/读者索取更多资源

R-spondins (RSPOs) amplify WNT signaling during development and regenerative responses. We previously demonstrated that RSPOs 2 and 3 potentiate WNT/beta-catenin signaling in cells lacking leucine-rich repeat-containing G-protein coupled receptors (LGRs) 4, 5 and 6 (Lebensohn and Rohatgi, 2018). We now show that heparan sulfate proteoglycans (HSPGs) act as alternative co-receptors for RSPO3 using a combination of ligand mutagenesis and ligand engineering. Mutations in RSPO3 residues predicted to contact HSPGs impair its signaling capacity. Conversely, the HSPG-binding domains of RSPO3 can be entirely replaced with an antibody that recognizes heparan sulfate (HS) chains attached to multiple HSPGs without diminishing WNT-potentiating activity in cultured cells and intestinal organoids. A genome-wide screen for mediators of RSPO3 signaling in cells lacking LGRs 4, 5 and 6 failed to reveal other receptors. We conclude that HSPGs are RSPO co-receptors that potentiate WNT signaling in the presence and absence of LGRs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据